Using the following cut-off values for the subjects with HCC (n = 95): 20 ng/dL for AFP, 7% for AFP-L3, 40 ng/mL for DCP, 0.0414 ng/mL for GPC, and 6.25 ng/mL for CK19, we found out that 80/95 (84.2%) patients had elevated AFP, 66 (69.5%) patients had elevated AFP-F3, and 94 (98.5%) patients had elevated DCP. The gene discussed is AFP; the disease is hepatocellular carcinoma.